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Background/aim: The aim of the current study was to screen the rate of MEFV mutations in Henoch–Schönlein purpura (HSP) and
to investigate the association of these mutations plus clinical symptoms with HSP disease in the Iranian Azari Turkish ethnic group.
Materials and methods: The study groups included 40 unrelated HSP patients and 200 apparently healthy people without any kind of
inflammatory diseases as a control group. Molecular screening was performed for eight main mutations, namely M694V, M694I, M680I,
V726A, E148Q, R761H, P396S, and R408Q, using polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP),
and sequencing.
Results: Out of the 40 studied patients, 27 subjects (67.5%) did not show any mutation, whereas 10 patients (25%) were heterozygotes
for one of the following mutations: M694V, M680I, V726A, E148Q. Moreover, three patients (7.5%) were compound heterozygotes for
P369S and R408Q. The significant differences between the patient and control groups for M680I, V726A, E148Q, P396S, and R408Q
were P = 0.0043, P = 0.0324, P = 0.0145, P = 0.0043, and P = 0.0043, respectively. Furthermore, no significant difference in clinical
manifestations was observed between the two groups of patients with and without mutations.
Conclusion: Based on the results, MEFV mutations could be considered effective genetic factors for development of HSP in the Iranian
Azari Turkish ethnic group.
Key words: MEFV mutations, Henoch–Schönlein purpura, vasculitis, Azari Turkish, Iran

1. Introduction
Henoch–Schönlein purpura (HSP) is one of the most
common types of systematic small vessel vasculitis
during childhood (1), with an incidence of 10–20
subjects per 100,000 people (2). HSP is a multifactorial
inflammatory disease that occurs from the age of 3 to
15, and it is more prevalent among boys (2). HSP is
normally described by deposition of immunoglobulin A
within the small blood vessel wall (3) and, according to
the diagnostic criteria of HSP, this disease would include
nonthrombocytopenic palpable purpura and at least one
of the other manifestations such as colicky abdominal
pain, arthritis, and renal involvement with hematuria and
proteinuria, which can progress towards renal failure (1).
Although HSP is generally self-limiting and the major
pathogenic cause of HSP is still unclear, it seems that
* Correspondence: jabbarpour@tabrizu.ac.ir

inflectional, environmental, and hereditary factors could
play important roles in the development and progress of
the disease (4).
Given the genetic variations in genes related to
cytokines and cell adhesion molecules, which are involved
in modulating inflammatory responses and endothelial
cell activation, several researchers have focused on
polymorphisms in related genes to study the probable
associations with HSP (2). In addition, recently the
connection between vasculitis such as HSP, Behçet disease
(BD), polyarteritis nodosa (PAN), and MEFV mutations
has been reported, i.e. the gene mutations in MEFV could
be regarded as an aspect that could have a considerable
effect on susceptibility to HSP and its progress (1).
The MEFV gene is located in 16p13.3 and has 10 exons
encoding a protein (pyrin/marenostrin) with multiple
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domains. To date, more than 80 different mutations in the
MEFV gene have been recognized and several mutations
in it are associated with the severity of diseases (5). Pyrin
could only be found in granulocytes and is involved in
inflammation and cell death regulation (5,6). This protein
is considered a crucial part of inflammatory response that
could have impact on gene expression, especially the genes
involved in immune and inflammatory responses (2).
The present study was planned to investigate the
prevalence of common and rare mutations of the MEFV
gene in Iranian Azari Turkish patients with HSP who had
not shown any sign of familial Mediterranean fever (FMF)
or other inflammatory diseases.
2. Materials and methods
2.1. Patients
Forty sequential unrelated patients with HSP who had
received a clinical diagnosis of HSP and 200 subjects who
were apparently healthy without any kind of inflammatory
diseases from the Iranian Azari Turkish ethnic group
were genetically screened in this study. All the patients
were informed about the study purposes and written
consent was obtained from the subjects or their parents.
In addition, the medical report and family history were
collected for each subject. Genomic DNA was extracted
from peripheral blood leukocytes using standard protocols
(7). This study was also approved by the Ethical Committee
of Tabriz University of Medical Sciences.
2.2. PCR amplification and digestion
In this research, eight main mutations in the MEFV gene
were analyzed using polymerase chain reaction (PCR)
amplification as previously described (6). In brief, the
E148Q, P369S, and R408Q mutations were detected by the
PCR and restriction fragment length polymorphism (PCRRFLP) technique, while M680I(G/C), M694I, M694V,
V726A, and R761H mutations were detected by the
amplification refractory mutation system (ARMS-PCR)
(6). In this process, positive and negative controls were
used for each test and the positive results were repeated to
ensure reproducibility (8). Finally, the accuracy of results
was verified by direct sequencing.
2.3. Statistical analysis
To compare the frequency of gene carriers, chi-square test
and Fisher’s exact test were applied (9). The odds ratios
(OR) and confidence intervals (CI) at the significance level
of 95% were calculated and reported for all the data (10).
Significant difference has been assigned to less than 0.05
(P-values < 0.05). Furthermore, the descriptive statistics
including percentage and median were used to analyze
the obtained data (1,11). Lastly, the chi-square test of
goodness-of-fit was utilized to test the Hardy–Weinberg
equilibrium.
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3. Results
In this study, ARMS-PCR, PCR-RFLP, and sequencing
procedures were exploited for molecular diagnosis of
eight mutations in HSP patients. The experimental group
consisted of 40 HSP patients (24 males and 16 females).
The ratio of males to females was 1.5 and the average of
age was 7.3 years (ranging from 3 to 13) at the time of HSP
diagnosis.
In the first step, eight MEFV mutations were screened
(12). Out of the 40 patients, 27 (67.5%) did not have any
mutations, while 13 (32.5%) had at least an MEFV mutation.
Molecular screening of the eight MEFV mutations, namely
M694V, M694I, M680I, V726A, E148Q, R761H, P396S,
and R408Q, revealed 10 people (25%) were heterozygotes
for one of the mutations (M694V in 1 patient, M680I in 3
patients, V726A in 4 patients, and E148Q in 2 patients),
while three people (7.5%) were compound heterozygotes
(P369S/R408Q in 2 patients, V726A/P369S/R408Q in
1 patient) and none of the patients were homozygous.
In this studied ethnic group, the mutations of M694V,
M680I, V726A, E148Q, P396S, and R408Q were observed
in 2.5%, 7.5%, 12.5%, 5%, 7.5%, and 7.5% of the patients,
respectively. Our results showed a significant difference in
frequencies of MEFV mutations between the HSP patient
and control groups (P-value = 0.0353). Moreover, it was
revealed that there was also a significant difference between
the mutation distributions in the two groups: M680I (P =
0.0043), V726A (P = 0.0324), E148Q (P = 0.0145), P396S
(P = 0.0043), and R408Q (P = 0.0043). In addition, the
frequency of M694V, M694I, and R761H mutations in the
patient group was not statistically different from that of the
control group (P = 0.1666, P = 1, and P = 1, respectively).
Totally, 17 mutated alleles were observed in 13 patients,
revealing that the mutated allele frequency was 0.21 in this
cohort. The distribution of MEFV mutations in the HSP
patient and control groups are shown in Table 1.
In the second step, the clinical parameters of the
patients with/without mutations were analyzed, which
showed that there was no significant difference between
the considered groups (Table 2). Moreover, in comparison
with the patients without MEFV mutations, arthritis and
arthralgia were more frequent, but insignificant, in the
patients with mutated alleles (10/13:15/27, P-value =
0.298 and 5/13:5/27, P-value = 0.246, respectively) (Table
2). Although the patients with MEFV mutations were
averagely younger than the patients without any mutation,
it did not show a significant difference (6.6 years and 7.9
years, respectively). This result is compatible with previous
reports (12,13) (not shown in the tables). The main clinical
characteristics of the patients were as follows: palpable
purpura in 40 patients (100%), joint involvement in 29
patients (72.5%), abdominal pain in 24 patients (60%),
renal involvement in 4 patients (10%), orchitis in 2 patients
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Table 1. Distribution and P-values of MEFV mutations in HSP patients and the control group.
Mutation

Patient group (n = 40)

Control group (n =2 00)

OR (95% CI)

M694V

1

0

0.1666

M694I

0

0

1

M680I

3

0

0.0043*

V726A

5

7

3.9388

0.0324*

E148Q

2

45

0.1813

0.0145*

R761H

0

0

1

P396S

3

0

0.0043*

R408Q

3

0

0.0043*

Total

17

52

2.1037

P-value

0.0353*

*P-values < 0.05

Table 2. Comparison of clinical features between patients with and without mutations.
Clinical feature

HSP with mutation (n = 13)

HSP without mutation (n = 27)

OR (95% CI)

P-value

Palpable purpura

13(100.0)

27(100.0)

Arthritis

10(76.9)

15(55.5)

2.666

0.298

Arthralgia

5(38.4)

5(18.5)

2.750

0.246

Joint involvement

12(92.3)

17(62.9)

7.0588

0.0678

Abdominal pain

8(61.5)

16(59.2)

1.1000

0.8414

Renal involvement

1(7.6)

3(11.1)

0.6667

1.0000

Orchitis

0(0.0)

2(7.4)

0.0000

0.5496

Fever

1(7.6)

2(7.4)

1.0417

1.0000

Nausea

0(0.0)

1(3.7)

0.0000

1.0000

Vomiting

1(7.6)

4(14.8)

0.4792

0.6532

1.0000

*P-values < 0.05

(5%), fever in 3 patients (7.5%), nausea in 1 patient (2.5%),
and vomiting in 5 patients (12.5%).
4. Discussion
HSP is an inflammatory multisystemic disorder with
unknown etiology. It seems that genetic and environmental
factors such as infections trigger the disease (9). Based on
some studies, genetic variants in human leukocyte antigen
(HLA), angiotensin converting enzyme (ACE), and the
MEFV gene may confer susceptibility on HSP (4). The
MEFV gene encodes the pyrine protein, which plays an
important role in inflammatory pathways by decreasing

inflammation, particularly in neutrophils; therefore,
the mutated protein might then cause uncontrolled
inflammation and predisposing development of HSP and
other types of vasculitis (13). It is proposed that mutation
carriers may show higher inflammatory responses with
severe clinical symptoms; moreover, research has indicated
that the abnormal clearance of immune complexes
and dysregulation of inflammatory response were due
to defective genetic loci (13). Hence, investigation of
MEFV mutations in HSP patients would be a useful
approach to follow up susceptible patients that could lead
to early diagnosis and treatment of HSP sufferers (13).
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Additionally, it has been reported that MEFV mutations
are more common in children with HSP symptoms, which
could have influential effects on our understanding about
the clinical manifestations and molecular mechanisms of
HSP (5). Previously, a comprehensive study described a
significant association between HSP and FMF (13). In this
regard, the high frequency of vasculitis in FMF patients
persuaded the researchers to study the MEFV mutations
in vasculitis, including HSP, PAN, Behçet disease,
inflammatory bowel disease, and rheumatic disease (14).
It is suggested that carrying out more investigations,
especially in populations with high prevalence of FMF
mutations, would lead to better understanding (4).
However, more efforts are necessary to identify the risky
patients to implement preventive treatment (4). With
regard to these observations, the present study investigated
the frequency and clinical significance of MEFV mutations
in HSP patients (14).
In the present paper, the spectrum and distribution
of eight MEFV mutations were screened in Iranian Azari
Turkish HSP patients. Observation showed some MEFV
mutations (M680I, V726A, E148Q, P396S, and R408Q)
could act as an additional genetic susceptibility factor in
HSP development. To confirm the suggested association, it
was proposed that further investigation should be carried
out to determine the ethnic differences in allelic frequency
of MEFV gene among HSP patients (8).
Molecular screening of eight MEFV mutations revealed
that ten people (25%) were heterozygous, whereas three
people (7.5%) were compound heterozygous for them.
In another study, Ozcakar et al. reported that 34% of 80
HSP patients had heterozygous MEFV mutations whereas
none of the patients showed homozygous or compound
heterozygous mutations (1). Other studies reported that
8% homozygous and 43% heterozygous subjects were
found in a Turkish population and the rates of homozygous

and heterozygous subjects in a Chinese population were
13% and 45%, respectively (2,5). Furthermore, GershoniBaruch stated that 27% of Israeli patients had at least a
single mutation in the MEFV gene (11).
In our cohort, 32.5% of HSP patients were carriers
of MEFV mutations compared with 26% in the control
group with the same ethnic background. The current
study is in agreement of Turkish and Chinese populations;
the prevalence of MEFV mutations in HSP patients was
significantly higher than in the normal population (Table
3) (5). Current findings were different from the result
obtained by Nikibakhsh et al., in which a high rate of
M694V mutations in HSP subjects was reported (15).
In contrast to the current findings, two other studies
conducted by Altug et al. and Bayram et al. revealed the
lower mutation rate for M694V in the HSP patient group
(12,13). However, none of the patients with HSP showed
the M694V mutation in a Chinese population (12). In this
study, the carrier rate of MEFV mutations in the control
group was 26% and more than half of these individuals
had the E148Q mutation. E148Q, located in exon 2, is
necessary to determine the cytoplasmic and nuclear
localization of pyrin protein within cells (12). With respect
to the insignificant differences of the E148Q mutation
between the experimental and control groups, it should be
noted that it may not be fully penetrant (9). It has been
suggested that the E148Q mutation is a mild mutation with
reduced penetrance, and a considerable number of patients
who were homozygous for the E148Q mutation remain
asymptomatic (9). In a study conducted in China, a 30%
mutation rate has been reported for E148Q in HSP patients
(12). They concluded that E148Q can be a contributory
genetic factor for HSP and its related syndrome and it
plays an important role in clinical phenotypes associated
with HSP (2,12). Given these findings, both M694V and
E148Q mutations seem to act very differently in HSP

Table 3. The distribution of mutations in previous studies.
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Authors

Country

HSP (n)

Mutation (+) n(%)

Gershoni et al.

Israel

52

14(26.9)

He et al.

China

78

27(34.6)

Özçakar et al.

Turkey

80

27(33.7)

Bayram et al.

Turkey

107

47(43.9)

Dogan et al.

Turkey

76

18(23.6)

Altug et al.

Turkey

68

18(26.4)

Nikibakhsh et al.

Iran

50

12(24.0)

Present study

Iran

40

13(32.5)
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patients from different ethnicities with different genetic
backgrounds; therefore, it is suggested they may not be
specifically related to HSP (12).
Although R761H was the most frequent mutation
among the rare mutations, no R761H mutation was found in
the patients with HSP (8). This means that it is possible our
patients carry new mutations (15). This study did not detect
any of the eight mutations in 63 of the 80 alleles studied
(78.75%). This could be due to multiple factors, including
the presence of unknown mutations in the promoter or
within intron regions, genetic heterogeneity, presence of
modifier genes, and unknown environmental factors (16).
The obtained results and a study performed in Israel indicate
that there is no statistically significant difference in clinical
manifestations between the patient groups with and without
mutations (5) but the patients with MEFV mutations were

on average younger than the patients without any mutation.
This result is compatible with previous reports that mutation
carrier patients were younger and more frequent, but not
statistically significant as P < 0.05 (12,14). Another study
revealed the MEFV mutations do not influence the clinical
symptoms of HSP (5). On the other hand, three other
studies (1,12,14) conducted in Turkey indicated that MEFV
mutations are important predisposing factors for HSP and
these mutations also could affect the clinical symptoms (2).
In conclusion, our study supports the notion that Iranian
Azari Turks are supposed to have a high risk of HSP
development and MEFV mutations can be a predisposing
factor (8).
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